Discover and read the best of Twitter Threads about #FIDELIO
Most recents (4)
1) Welcome to our new #tweetorial on optimizing #interprofessional & #multidisciplinary care & medical therapy for patients with #DKD. I am Sophia Ambruso DO, @Sophia_kidney, from @CU_kidney. 
2) This #accredited #tweetorial series on #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers. Faculty disclosures are at ckd-ce.com/disclosures/.
3) This activity is accredited for 0.75h credit for #physicians #physicianassociates #nurses #NPs #pharmacists. Past programs still eligible for credit can be found at ckd-ce.com. FOLLOW US for more programs by expert faculty!
1) Welcome to our new #accredited #tweetorial on #mechanismofaction & impact of meds commonly used in patients with or at risk for #DKD progression: #MRAs, #GLP-1 receptor agonists & #DPP-4 inhibitors. I am Sophia Ambruso DO, @sophia_kidney, from @CU_Kidney.
2) This #accredited #tweetorial series on #kidneydisease #DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.
3) This activity is accredited for #physicians #physicianassociates #nurses #NPs #pharmacists. Past programs still eligible for credit can be found at ckd-ce.com. Faculty disclosures are at ckd-ce.com/disclosures/. FOLLOW US for regular programs by expert faculty!
Exploring the cardiorenal benefits of MR antagonism in CKD and T2D
📌Finerenone - Novel , selective , non- steroidal MRA
#ESCCongress @lamcardio @BiykemB @MihaiTrofenciuc @pabeda1 @AndrewJSauer @MeralKayikcoglu @ErinMichos @DrMarthaGulati @DavidLBrownMD @JamalRanaMD
📌Finerenone - Novel , selective , non- steroidal MRA
#ESCCongress @lamcardio @BiykemB @MihaiTrofenciuc @pabeda1 @AndrewJSauer @MeralKayikcoglu @ErinMichos @DrMarthaGulati @DavidLBrownMD @JamalRanaMD
Finerenone has a favorable safety profile across a wide dose range in patients with CKD and T2DM receiving a RAS blocker
#ESCCongress
@CMichaelGibson @JamalRanaMD @DrMarthaGulati @AnastasiaSMihai @onco_cardiology @DavidLBrownMD @biljana_parapid @AndrewJSauer @ShelleyZieroth
#ESCCongress
@CMichaelGibson @JamalRanaMD @DrMarthaGulati @AnastasiaSMihai @onco_cardiology @DavidLBrownMD @biljana_parapid @AndrewJSauer @ShelleyZieroth
New promising player to protect Kidney and Heart in CV Medicine
#ESCCongress @escardio @ESC_Lavinia @TheLancetEndo @kidney_boy @Nephro_Sparks @ASNKidney @NephJC @DBelardoMD @NephroGuy @lipiddoc @AnastasiaSMihai @MihaiTrofenciuc @MiguelCamafort @Steph_Achenbach
#ESCCongress @escardio @ESC_Lavinia @TheLancetEndo @kidney_boy @Nephro_Sparks @ASNKidney @NephJC @DBelardoMD @NephroGuy @lipiddoc @AnastasiaSMihai @MihaiTrofenciuc @MiguelCamafort @Steph_Achenbach
Finerenone reduces decline of GFR and key secondary outcomes. Hyperkalemia was not really an issue #Kidneywk
Very safe drug in a trial context. Less hyperK than with spironolactone #kidneywk
